Skip to main content
Medistim logo

Medistim — Investor Relations & Filings

Ticker · MEDI ISIN · NO0010159684 LEI · 5967007LIEEXZXJOX483 OL Manufacturing
Open in API
Filings indexed 783 across all filing types
Latest filing 2018-10-22 Legal Proceedings Report
Country NO Norway
Listing OL MEDI

About Medistim

https://medistim.com/

Medistim is a medical technology company specializing in intraoperative quality assessment solutions. A pioneer and market leader in Transit Time Flow Measurement (TTFM), the company develops and manufactures advanced medical devices for use during surgical procedures. Its flagship MiraQ™ system uniquely combines TTFM with high-frequency ultrasound imaging, providing surgeons with real-time data to verify graft function and blood flow. This technology is applied in cardiac, vascular, and transplant surgery to enhance procedural quality control and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Endelige resultater fra REQUEST studien presentert på EACTS
Legal Proceedings Report Classification · 99% confidence The document is a press release from Medistim ASA announcing the final results of the REQUEST registry study, which were presented at the EACTS conference. It details clinical findings, quotes the CEO and the lead professor, and concludes with standard company information and contact details. This type of announcement, focusing on the release of significant clinical or research findings outside of standard periodic financial reporting (like 10-K or IR), typically falls under a general regulatory announcement or investor relations communication. Since it is not a full financial report (10-K, IR), a transcript (CT), or a specific management/governance filing, it best fits the category for general regulatory announcements or investor news. Given the content is a formal announcement of study results intended for investors and the market, it aligns most closely with a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were the slides themselves, but as a press release announcing results, RNS is the most appropriate fallback for significant, non-standard disclosures.
2018-10-22 Norwegian
Final results from the REQUEST study presented at EACTS
Regulatory Filings Classification · 99% confidence The document announces the final results of a clinical study (REQUEST study) presented at a medical conference (EACTS). It details the study's objective, methodology, key findings (e.g., surgical changes, revision rates, mortality), and includes quotes from the lead investigator and the company CEO. This content is characteristic of a press release or an announcement regarding clinical data or research findings, rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive quarterly report (IR). Since it is an announcement of specific research results and clinical data, it fits best under the general 'Regulatory Filings' (RNS) category as a specific corporate announcement that doesn't match the other specialized codes (like DIV, CAP, or ER). It is not a presentation (IP) or a transcript (CT). Given the context of disclosing specific, non-financial operational/clinical results, RNS is the most appropriate fallback.
2018-10-22 English
Presentasjon av resultater for 3. kvartal 2018 for Medistim ASA
Report Publication Announcement Classification · 93% confidence The document text is very short (439 characters) and announces an upcoming presentation regarding the results for the 3rd quarter of 2018 for Medistim ASA. It specifies the time, date, and location of this presentation and lists the attending executives (CEO, CFO). This is an announcement inviting stakeholders to an event where results will be discussed, which strongly aligns with the definition of a Call Transcript (CT) if the transcript were present, or more likely, an Investor Presentation (IP) or a general announcement related to earnings. Since it is an invitation to a presentation of quarterly results, it is most closely related to the materials presented during an earnings call or investor meeting. Given the context of quarterly results announcement, and the invitation to a presentation, 'Investor Presentation' (IP) is a strong candidate, although 'Call Transcript' (CT) is often used for the event itself. However, since this is an invitation to the presentation, and not the presentation slides or the transcript itself, it functions as a preliminary announcement. If the presentation slides were attached, it would be IP. If the transcript were present, it would be CT. As a short announcement about the presentation event for quarterly results, it is often grouped with earnings-related materials. Given the options, and the focus on the presentation event for quarterly results, 'Investor Presentation' (IP) is the most fitting category for the underlying material being discussed, or 'Call Transcript' (CT) if this were the invitation to the call itself. Since it explicitly mentions 'Presentasjon av resultater' (Presentation of results), IP is slightly better than CT (which implies the transcript). However, in many databases, the announcement of the earnings call/presentation is often categorized under the general earnings release (ER) or the presentation itself (IP). Given the explicit mention of a 'presentation' of quarterly results, I will classify it as Investor Presentation (IP).
2018-10-18 Norwegian
Presentation of third quarter results 2018 for Medistim ASA
Report Publication Announcement Classification · 95% confidence The document text explicitly states it is a 'Presentation of third quarter results 2018' and invites attendees to a presentation event, listing the CEO and CFO who will be present. This strongly indicates materials related to an earnings event or investor briefing, but it is not the full transcript (CT) or the formal earnings release (ER) itself, but rather the presentation materials used during that event. The closest fit among the provided definitions is Investor Presentation (IP), as it is a presentation summarizing quarterly results.
2018-10-18 English
Resultater for 2. kvartal og første halvår 2018 for Medistim ASA
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for Medistim ASA covering the second quarter and first half of 2018. It contains detailed financial statements (Profit and Loss, Balance Sheet), business segment updates, and management analysis of revenue performance. It is not a short announcement or a certification, but the actual interim financial report itself, fitting the definition of an Interim / Quarterly Report (IR). H1 2018
2018-08-15 Norwegian
Results for the second quarter and first half 2018 for Medistim ASA
Interim / Quarterly Report Classification · 100% confidence The document is titled '2nd quarter and 1st half report for 2018' and contains detailed financial statements, including sales, operating profit (EBIT), EBITDA, balance sheet data, and operational status updates for various geographic regions. It provides comprehensive financial analysis for a period shorter than a full fiscal year, which fits the definition of an Interim/Quarterly Report. H1 2018
2018-08-15 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.